Ref003 07 Treatment

<<< Refs

2 May 2020


Agostini 2018
Agostini ML, Andres EL, Sims AC, et al. Coronavirus Susceptibility to the Anti-viral Remdesivir (GS-5734) Is Mediated by the Viral Polymerase and the Proofreading Exoribonuclease. mBio. 2018 Mar 6;9(2). pii: mBio.00221-18. PubMed: Full-text:

Arabi 2017
Arabi YM, Balkhy HH, Hayden FG, et al. Middle East Respiratory Syndrome. N Engl J Med. 2017 Feb 9;376(6):584-594. PubMed: Full-text:

Arabi 2019
Arabi YM, Shalhoub S, Mandourah Y, et al. Ribavirin and Interferon Therapy for Critically Ill Patients With Middle East Respiratory Syndrome: A Multicenter Observational Study. Clin Infect Dis. 2019 Jun 25. pii: 5523209. PubMed: Full-text:

Baron 2020
Baron SA, Devaux C, Colson P, Raoult D, Rolain JM. Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19? Int J Antimicrob Agents. 2020 Mar 13:105944. PubMed: Full-text:

Bartiromo 2020
Bartiromo M, Borchi B, Botta A, et al. Threatening drug-drug interaction in a kidney transplant patient with Coronavirus Disease 2019 (COVID-19). Transpl Infect Dis. 2020 Apr 12. PubMed: Full-text:

Bleibtreu 2016
Bleibtreu A, Jaureguiberry S, Houhou N, et al. Clinical management of respira-tory syndrome in patients hospitalized for suspected Middle East res-piratory syndrome coronavirus infection in the Paris area from 2013 to 2016. BMC Infect Dis. 2018 Jul 16;18(1):331. PubMed: Full-text:

Bloch 2020
Bloch EM, Shoham S, Casadevall A, et al. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest. 2020 Apr 7. pii: 138745. PubMed: Full-text:

Bryner J. Flu drug used in Japan shows promise in treating COVID-19.

Cao 2020
Cao B, Wang Y, Wen D, et al. A Trial of Lopinavir-Ritonavir in Adults Hospital-ized with Severe Covid-19. N Engl J Med. 2020 Mar 18. PubMed: Full-text:

Casadevall 2020
Casadevall A, Pirofski LA. The convalescent sera option for containing COVID-19. J Clin Invest. 2020 Mar 13. pii: 138003. PubMed: Full-text:

Chan 2003
Chan KS, Lai ST, Chu CM, et al. Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study. Hong Kong Med J. 2003 Dec;9(6):399-406 PubMed: Full-text:

Channappanavar 2017
Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017 Jul;39(5):529-539. PubMed: Full-text:

Chen 2020
Chen C, Huang J, Cheng Z, et al. Favipiravir versus Arbidol for COVID-19: A Randomized Clinical Trial. Posted March 27, medRxiv 2020.03.17.20037432;

Chen J, Danping L, Liu L, et al. A pilot study of hydroxychloroquine in treatment of patients with common coronavirus disease-19. J Zhejiang University. March 2020

Chen 2020
Chen N, Zhou M, Dong X, et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a de-scriptive study. Lancet. 2020 Feb 15;395(10223):507-513. PubMed: Full-text:

Chen 2006
Chen RC, Tang XP, Tan SY, et al. Treatment of severe acute respiratory syn-drome with glucosteroids: the Guangzhou experience. Chest. 2006 Jun;129(6):1441-52. PubMed: Full-text:

Chen 2020
Chen YW, Yiu CB, Wong KY. Prediction of the SARS-CoV-2 (2019-nCoV) 3C-like protease (3CL (pro)) structure: virtual screening reveals velpatasvir, ledipasvir, and other drug repurposing candidates. F1000Res. 2020 Feb 21;9:129. PubMed: Full-text:

Chu 2004
Chu CM, Cheng VC, Hung IF, et al. Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings. Thorax. 2004 Mar;59(3):252-6. PubMed: Full-text:

Cockrell 2016
Cockrell AS, Yount BL, Scobey T, et al. A mouse model for MERS coronavirus-induced acute respiratory distress syndrome. Nat Microbiol. 2016 Nov 28;2:16226. PubMed: Full-text:

Delang 2018
Delang L, Abdelnabi R, Neyts J. Favipiravir as a potential countermeasure against neglected and emerging RNA viruses. Antiviral Res. 2018 May;153:85-94. PubMed: Full-text:

Deng 2020
Deng L, Li C, Zeng Q, et al. Arbidol combined with LPV/r versus LPV/r alone against Corona Virus Disease 2019: A retrospective cohort study. J Infect. 2020 Mar 11. pii: S0163-4453(20)30113-4. PubMed: Full-text:

Di 2020
Di Giambenedetto S, Ciccullo A, Borghetti A, et al. Off-label Use of Tocilizumab in Patients with SARS-CoV-2 Infection. J Med Virol. 2020 Apr 16. PubMed: Full-text:

Du 2020
Du YX, Chen XP. Favipiravir: pharmacokinetics and concerns about clinical trials for 2019-nCoV infection. Clin Pharmacol Ther. 2020 Apr 4. PubMed: Full-text:

Duan 2020
Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-19 patients. PNAS 2020, April 6.

EC. 2020
EC. Expert consensus on chloroquine phosphate for the treatment of novel coronavirus pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020 Mar 12;43(3):185-188.

Elfiky 2020
Elfiky AA. Anti-HCV, nucleotide inhibitors, repurposing against COVID-19. Life Sci. 2020 May 1;248:117477. PubMed: Full-text:

Falzarano 2013
Falzarano D, de Wit E, Rasmussen AL, et al. Treatment with interferon-alpha2b and ribavirin improves outcome in MERS-CoV-infected rhesus ma-caques. Nat Med. 2013 Oct;19(10):1313-7. PubMed: Full-text:

Ferner 2020
Ferner RE, Aronson JK. Chloroquine and hydroxychloroquine in covid-19. BMJ. 2020 Apr 8;369:m1432. PubMed: Full-text:

Gao 2020
Gao J, Tian Z, Yang X. Breakthrough: Chloroquine phosphate has shown ap-parent efficacy in treatment of COVID-19 associated pneumonia in clinical studies. Biosci Trends. 2020 Mar 16;14(1):72-73. PubMed: Full-text:

Gautret 2020
Gautret P, Lagier JC, Parola P, et al. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020 Mar 20:105949. PubMed: Full-text:

Grein 2020
Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med. 2020 Apr 10. PubMed: Full-text:

Guastalegname 2020
Guastalegname M, Vallone A. Could chloroquine /hydroxychloroquine be harm-ful in Coronavirus Disease 2019 (COVID-19) treatment? Clin Infect Dis. 2020 Mar 24. pii: 5811416. PubMed: Full-text:

Hillaker 2020
Hillaker E, Belfer JJ, Bondici A, Murad H, Dumkow LE. Delayed Initiation of Remdesivir in a COVID-19 Positive Patient. Pharmacotherapy. 2020 Apr 13. PubMed: Full-text:

Hoffmann 2020
Hoffmann M, Kleine-Weber H, Krüger N, Müller M, Drosten C, Pöhlmann S. The novel coronavirus 2019 (2019-nCoV) uses the SARS-coronavirus receptor ACE2 and the cellular protease TMPRSS2 for entry into target cells. 2020.

Hoffmann 2020
Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor. Cell. 2020 Mar 4. pii: S0092-8674(20)30229-4. PubMed: Full-text:

Holshue 2020
Holshue ML, DeBolt C, Lindquist S, et al. First Case of 2019 Novel Coronavirus in the United States. N Engl J Med. 2020 Mar 5;382(10):929-936. PubMed: Full-text:

Ji 2020
Ji Y, Ma Z, Peppelenbosch MP, Pan Q. Potential association between COVID-19 mortality and health-care resource availability. Lancet Glob Health. 2020 Apr;8(4):e480. PubMed: Full-text:

Jin 2020
Jin Z, Du X, Xu Y, et al. Structure of M(pro) from COVID-19 virus and discovery of its inhibitors. Nature. 2020 Apr 9. pii: 10.1038/s41586-020-2223-y. PubMed: Full-text:

Kawase 2012
Kawase M, Shirato K, van der Hoek L, Taguchi F, Matsuyama S. Simultaneous treatment of human bronchial epithelial cells with serine and cysteine protease inhibitors prevents severe acute respiratory syndrome coro-navirus entry. J Virol. 2012 Jun;86(12):6537-45. PubMed: Full-text:

Kim 2020
Kim AH, Sparks JA, Liew JW. A Rush to Judgment? Rapid Reporting and Dis-semination of Results and Its Consequences Regarding the Use of Hy-droxychloroquine for COVID-19. Ann Intern Med 2020. DOI:

Lim 2020
Lim J, Jeon S, Shin HY, et al. Case of the Index Patient Who Caused Tertiary Transmission of COVID-19 Infection in Korea: the Application of Lop-inavir/Ritonavir for the Treatment of COVID-19 Infected Pneumonia Monitored by Quantitative RT-PCR. J Korean Med Sci. 2020 Feb 17;35(6):e79. PubMed: Full-text:

Ling 2020
Ling Y, Xu SB, Lin YX, et al. Persistence and clearance of viral RNA in 2019 novel coronavirus disease rehabilitation patients. Chin Med J (Engl). 2020 Feb 28. PubMed: Full-text:

Liu 2020
Liu F, Xu A, Zhang Y, et al. Patients of COVID-19 may benefit from sustained lopinavir-combined regimen and the increase of eosinophil may predict the outcome of COVID-19 progression. Int J Infect Dis. 2020 Mar 12. pii: S1201-9712(20)30132-6. PubMed: Full-text:

Mair-Jenkins 2015
Mair-Jenkins J, Saavedra-Campos M, Baillie JK, et al. The effectiveness of conva-lescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis. J Infect Dis. 2015 Jan 1;211(1):80-90. PubMed: Full-text:

McKee 2020
McKee S. Positive early data from siltuximab COVID-19 trial. 2nd April 2020.

Mehta 2020
Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020 Mar 16. pii: S0140-6736(20)30628-0. PubMed: Full-text:

Mihai 2020
Mihai C, Dobrota R, Schroder M, et al. COVID-19 in a patient with systemic scle-rosis treated with tocilizumab for SSc-ILD. Ann Rheum Dis. 2020 Apr 2. pii: annrheumdis-2020-217442. PubMed: Full-text:

Morse 2020
Morse JS, Lalonde T, Xu S, Liu WR. Learning from the Past: Possible Urgent Prevention and Treatment Options for Severe Acute Respiratory Infec-tions Caused by 2019-nCoV. Chembiochem. 2020 Mar 2;21(5):730-738. PubMed: Full-text:

Mulangu 2019
Mulangu S, Dodd LE, Davey RT Jr, et al. A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. N Engl J Med. 2019 Dec 12;381(24):2293-2303. PubMed: Full-text:

Omrani 2014
Omrani AS, Saad MM, Baig K, et al. Ribavirin and interferon alfa-2a for severe Middle East respiratory syndrome coronavirus infection: a retrospective cohort study. Lancet Infect Dis. 2014 Nov;14(11):1090-1095. PubMed: Full-text:

Park 2019
Park SY, Lee JS, Son JS, et al. Post-exposure prophylaxis for Middle East res-piratory syndrome in healthcare workers. J Hosp Infect. 2019 Jan;101(1):42-46. PubMed: Full-text:

Perinel 2020
Perinel S, Launay M, Botelho-Nevers E, et al. Towards Optimization of Hy-droxychloroquine Dosing in Intensive Care Unit COVID-19 Patients. Clin Infect Dis. 2020 Apr 7. pii: 5816960. PubMed: Full-text:

PR Press release. Favipiravir.

PR. Press release. Abidol and darunavir can effectively inhibit coronavirus. (accessed February 21, 2020).

Praveen 2020
Praveen D, Chowdary PR, Aanandhi MV. Baricitinib – a januase kinase inhibitor – not an ideal option for management of COVID-19. Int J Antimicrob Agents. 2020 Apr 4:105967. PubMed: Full-text:

Richardson 2020
Richardson P, Griffin I, Tucker C, et al. Baricitinib as potential treatment for 2019-nCoV acute respiratory disease. Lancet. 2020 Feb 15;395(10223):e30-e31. PubMed: Full-text:

Rome 2020
Rome BN, Avorn J. Drug Evaluation during the Covid-19 Pandemic. N Engl J Med. 2020 Apr 14. PubMed: Full-text:

Russell 2020
Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 2020 Feb 15;395(10223):473-475. PubMed: Full-text:

Savarino 2003
Savarino A, Boelaert JR, Cassone A, Majori G, Cauda R. Effects of chloroquine on viral infections: an old drug against today´s diseases? Lancet Infect Dis. 2003 Nov;3(11):722-7. PubMed: Full-text:

Sayburn 2020
Sayburn A. Covid-19: trials of four potential treatments to generate “robust data” of what works. BMJ. 2020 Mar 24;368:m1206. PubMed: Full-text:

Shalhoub 2015
Shalhoub S, Farahat F, Al-Jiffri A, et al. IFN-alpha2a or IFN-beta1a in combina-tion with ribavirin to treat Middle East respiratory syndrome corona-virus pneumonia: a retrospective study. J Antimicrob Chemother. 2015 Jul;70(7):2129-32. PubMed: Full-text:

Shang 2020
Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet. 2020 Feb 29;395(10225):683-684. PubMed: Full-text:

Shanmugaraj 2020
Shanmugaraj B, Siriwattananon K, Wangkanont K, Phoolcharoen W. Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19). Asian Pac J Allergy Immunol. 2020 Mar;38(1):10-18. PubMed: Full-text:

Sheahan 2017
Sheahan TP, Sims AC, Graham RL, et al. Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses. Sci Transl Med. 2017 Jun 28;9(396). pii: 9/396/eaal3653. PubMed: Full-text:

Sheahan 2020
Sheahan TP, Sims AC, Leist SR, et al. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV. Nat Commun. 2020 Jan 10;11(1):222. PubMed: Full-text:

Shen 2020
Shen C, Wang Z, Zhao F, et al. Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma. JAMA. 2020 Mar 27. pii: 2763983. PubMed: Full-text:

Shiraki 2020
Shiraki K, Daikoku T. Favipiravir, an anti-influenza drug against life-threatening RNA virus infections. Pharmacol Ther. 2020 Feb 22:107512. PubMed: Full-text:

Stebbing 2020
Stebbing J, Phelan A, Griffin I, et al. COVID-19: combining antiviral and anti-inflammatory treatments. Lancet Infect Dis. 2020 Feb 27. pii: S1473-3099(20)30132-8. PubMed: Full-text:

Stockman 2006
Stockman LJ, Bellamy R, Garner P. SARS: systematic review of treatment effects. PLoS Med. 2006 Sep;3(9):e343. PubMed: Full-text:

Tanne 2020
Tanne JH. Covid-19: FDA approves use of convalescent plasma to treat criti-cally ill patients. BMJ. 2020 Mar 26;368:m1256. PubMed: Full-text:

Touret 2020
Touret F, de Lamballerie X. Of chloroquine and COVID-19. Antiviral Res. 2020 Mar 5;177:104762. PubMed: Full-text:

Vincent 2005
Vincent MJ, Bergeron E, Benjannet S, et al. Chloroquine is a potent inhibitor of SARS coronavirus infection and spread. Virol J. 2005 Aug 22;2:69. PubMed: Full-text:

Wang 2020
Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020 Mar;30(3):269-271. PubMed: Full-text:

Wang 2020
Wang Z, Chen X, Lu Y, Chen F, Zhang W. Clinical characteristics and therapeutic procedure for four cases with 2019 novel coronavirus pneumonia receiving combined Chinese and Western medicine treatment. Biosci Trends. 2020 Mar 16;14(1):64-68. PubMed: Full-text:

WHO. Clinical management of severe acute respiratory infection when novel coronavirus (nCoV) infection is suspected. March 13

Wu 2020
Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med. 2020 Mar 13. pii: 2763184. PubMed: Full-text:

Wu 2020
Wu D, Yang XO. TH17 responses in cytokine storm of COVID-19: An emerging target of JAK2 inhibitor Fedratinib. J Microbiol Immunol Infect. 2020 Mar 11. pii: S1684-1182(20)30065-7. PubMed: Full-text:

Wu 2020
Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19). J Intern Med. 2020 Mar 27. PubMed: Full-text:

Xu X, Han M, Li T. Effective treatment of severe COVID-19 patients with Tocil-izumab. chinaXiv:202003.00026v1

Yan 2013
Yan Y, Zou Z, Sun Y, et al. Anti-malaria drug chloroquine is highly effective in treating avian influenza A H5N1 virus infection in an animal model. Cell Res. 2013 Feb;23(2):300-2. PubMed: Full-text:

Yao 2020
Yao X, Ye F, Zhang M, et al. In Vitro Antiviral Activity and Projection of Opti-mized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Clin Infect Dis. 2020 Mar 9. pii: 5801998. PubMed: Full-text:

Yazdany 2020
Yazdany J, Kim AH. Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know. Ann Intern Med. 2020. Full-text:

Young 2020
Young BE, Ong SWX, Kalimuddin S, et al. Epidemiologic Features and Clinical Course of Patients Infected With SARS-CoV-2 in Singapore. JAMA. 2020 Mar 3. pii: 2762688. PubMed: Full-text:

Zhang 2020
Zhang L, Lin D, Sun X, et al. Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved alpha-ketoamide inhibitors. Science. 2020 Mar 20. pii: science.abb3405. PubMed: Full-text:

Zhao 2020
Zhao JP, Hu Y, Du RH, et al. Expert consensus on the use of corticosteroid in patients with 2019-nCoV pneumonia. Zhonghua Jie He He Hu Xi Za Zhi 2020 Mar 12;43(3):183-184. Full-text:

Zhou 2020
Zhou P, Yang XL, Wang XG, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020 Mar;579(7798):270-273. PubMed: Full-text:

Zhu 2020
Zhu Z, Lu Z, Xu T, et al. Arbidol Monotherapy is Superior to Lopinavir/ritonavir in Treating COVID-19. J Infect. 2020 Apr 10. pii: S0163-4453(20)30188-2. PubMed: Full-text:

Zumla 2015
Zumla A, Azhar EI, Arabi Y, et al. Host-directed therapies for improving poor treatment outcomes associated with the middle east respiratory syn-drome coronavirus infections. Int J Infect Dis. 2015 Nov;40:71-4. PubMed: Full-text:

Zumla 2020
Zumla A, Hui DS, Azhar EI, Memish ZA, Maeurer M. Reducing mortality from 2019-nCoV: host-directed therapies should be an option. Lancet. 2020 Feb 22;395(10224):e35-e36. PubMed: Full-text: